Human AGER Protein

Cat. No. AER-HM101



Description	
Source	Recombinant Human AGER Protein is expressed from HEK293 with His tag at the C-Terminus.
	It contains Ala23- Ala344.
Accession	Q15109-1
Molecular Weight	The protein has a predicted MW of 35.3 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor upregulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.

Assay Data

Bis-Tris PAGE




Human AGER on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC


KAGTUS

Assay Data



The purity of Human AGER is greater than 95% as determined by SEC-HPLC.

SPR Data



Human AGER, His Tag immobilized on CM5 Chip can bind Human HMGB1, His Tag with an affinity constant of 0.19 μ M as determined in SPR assay (Biacore T200).